Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
Regnstrom, J. et al. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. Eur. J. Clin. Pharmacol. 66, 39–48 (2010).
Eichler, H. G. et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin. Pharmacol. Ther. 91, 425–437 (2012).
Eichler, H.-G. et al. Access to patient-level trial data — a boon to drug developers. N. Engl. J. Med. 369, 1577–1570 (2013).
Acknowledgements
We are most grateful to N. Zafiropoulos for his assistance with the EMA database, and to M. Posch, A. Elsäßer and L. Guizzaro for their advice on the statistical analysis.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
FURTHER INFORMATION
Supplementary information
Supplementary information S1 (box)
Terminology and analysis methods (PDF 88 kb)
Supplementary information S2 (Table)
Approved marketing authorization applications for drugs in psychiatry and neurology from 1995 to 2013 (PDF 89 kb)
Supplementary information S3 (box)
Additional information and analyses (PDF 227 kb)
Rights and permissions
About this article
Cite this article
Butlen-Ducuing, F., Zienowicz, M., Pétavy, F. et al. European regulatory experience with drugs for central nervous system disorders. Nat Rev Drug Discov 14, 89–90 (2015). https://doi.org/10.1038/nrd4511
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd4511
